⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8620821 | 0.77 | — | — | |
| SCHEMBL215239 | 0.64 | — | — | |
| SCHEMBL10935127 | 0.64 | — | — | |
| SCHEMBL8618924 | 0.61 | NOTUM (0.36) | — | |
| SCHEMBL2346494 | 0.61 | — | — | |
| SCHEMBL220383 | 0.60 | — | — | |
| SCHEMBL8618626 | 0.58 | NOTUM (0.39) | — | |
| SCHEMBL7273937 | 0.57 | — | — | |
| SCHEMBL8158776 | 0.57 | — | — | |
| SCHEMBL1136777 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031478-A | Triazolopyrazine use of ketone compounds | 昆明医科大学 | 2026-05-15 | — | — | CN | claimed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | claimed |
| JP-2002519373-A | — | — | 2002-07-02 | — | — | JP | claimed |
| EP-1100504-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | Eisai Co., Ltd. (JP) | 2001-05-23 | — | — | EP | claimed |
| WO-2000001376-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | EISAI CO., LTD (JP) | 2000-01-13 | — | — | WO | claimed |
| CN-122031478-A | Triazolopyrazine use of ketone compounds | 昆明医科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122031478-A | Triazolopyrazine use of ketone compounds | 昆明医科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-117447475-A | Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors | H.隆德贝克有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3529250-B1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2023-12-06 | — | — | EP | disclosed |
| CN-111511742-B | Pyrazolo [4,3-b ] pyridines and imidazo [1,5-a ] pyrimidines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111699188-B | [1,2,4] triazolo [4,3-a ] pyrazin-8-one derivatives | 伊莱利利公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-3749671-B1 | [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-8-ONE DERIVATIVES | LILLY CO ELI (US) | 2023-03-29 | — | — | EP | disclosed |
| US-9073927-B2 | Inhibitors of PI3 kinase | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2015-07-07 | — | — | US | disclosed |
| US-20130196986-A1 | TRIAZOLOPYRAZINONES AS P2X7 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2013-08-01 | — | — | US | disclosed |
| EP-2619204-A2 | TRIAZOLOPYRAZINONES AS P2X7 RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130131057-A1 | NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO (ES) | 2013-05-23 | — | — | US | disclosed |
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2013-02-28 | — | — | US | disclosed |
| WO-2012040048-A2 | TRIAZOLOPYRAZINONES AS P2X7 RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011141713-A1 | NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011089400-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-28 | — | — | WO | disclosed |